COVID 19 is the #10 most commonly reported adverse reaction for TACROLIMUS OINTMENT 0.1%, manufactured by Encube Ethicals, Inc.. There are 3,631 FDA adverse event reports linking TACROLIMUS OINTMENT 0.1% to COVID 19. This represents approximately 2.0% of all 181,625 adverse event reports for this drug.
TACROLIMUS OINTMENT 0.1% has an overall safety score of 92 out of 100. Patients taking TACROLIMUS OINTMENT 0.1% who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
COVID 193,631 of 181,625 reports
COVID 19 is a less commonly reported adverse event for TACROLIMUS OINTMENT 0.1%, but still significant enough to appear in the safety profile.
Other Side Effects of TACROLIMUS OINTMENT 0.1%
In addition to covid 19, the following adverse reactions have been reported for TACROLIMUS OINTMENT 0.1%:
COVID 19 has been reported as an adverse event in 3,631 FDA reports for TACROLIMUS OINTMENT 0.1%. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is COVID 19 with TACROLIMUS OINTMENT 0.1%?
COVID 19 accounts for approximately 2.0% of all adverse event reports for TACROLIMUS OINTMENT 0.1%, making it a notable side effect.
What should I do if I experience COVID 19 while taking TACROLIMUS OINTMENT 0.1%?
If you experience covid 19 while taking TACROLIMUS OINTMENT 0.1%, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.